Sugi Predict

Sugi Predict / Targets / MARK3

MARK3

MAP/microtubule affinity-regulating kinase 3 · P27448 · MARK3 on Sugi Atlas →

92,665 patent compounds predicted against MARK3, 69,097 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL95142 SCHEMBL95142 1.00 3/20
SCHEMBL94964 SCHEMBL94964 0.79 3/20
SCHEMBL58313 SCHEMBL58313 0.59 3/20
SCHEMBL58543 SCHEMBL58543 0.57 3/20
SCHEMBL60464 SCHEMBL60464 0.57 3/20
SCHEMBL58550 SCHEMBL58550 0.55 3/20
SCHEMBL59884 SCHEMBL59884 0.54 3/20
SCHEMBL58416 SCHEMBL58416 0.50 3/20
SCHEMBL59547 SCHEMBL59547 0.49 3/20
SCHEMBL60289 SCHEMBL60289 0.48 3/20
SCHEMBL58735 SCHEMBL58735 0.47 3/20
SCHEMBL60366 SCHEMBL60366 0.45 3/20
Sunitinib Sunitinib (SCHEMBL8081) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL8082) 1.00 2/20
Ripasudil Ripasudil (SCHEMBL31542) 1.00 2/20
SCHEMBL124161 SCHEMBL124161 1.00 2/20
SCHEMBL94862 SCHEMBL94862 0.97 2/20
SCHEMBL98692 SCHEMBL98692 0.92 2/20
Sunitinib Sunitinib (SCHEMBL18648) 0.92 2/20
Sunitinib Sunitinib (SCHEMBL55459) 0.84 2/20

Clinical trials — most relevant to MARK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PHASE4COMPLETED
Lithium for Prevention of Cognitive Declining in Mood Illnesses PHASE4NOT_YET_RECRUITING
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation PHASE4COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Evaluation of Serum Autophagic Biomarkers in the Acute Response to Walking and Cycling in Healthy Male Individuals nanENROLLING_BY_INVITATION
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Evaluation of a Novel PET Radioligand to Image OGA nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Muscle Wasting in Cancer (MWIC) nanCOMPLETED
Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MARK3 binder may also engage these)

ProteinNameSimilarity
Q03141 — 1.000 Q03141 →
O08679 — 1.000 O08679 →
Q05512 — 1.000 Q05512 →
MARK2 Serine/threonine-protein kinase MARK2 1.000 landscape →
Q8VHF0 — 1.000 Q8VHF0 →
O08678 — 1.000 O08678 →
MARK1 Serine/threonine-protein kinase MARK1 1.000 landscape →
Q8VHJ5 — 0.999 Q8VHJ5 →
Q2QMH1 — 0.996 Q2QMH1 →
Q19469 — 0.995 Q19469 →
P06782 — 0.993 P06782 →
P52497 — 0.992 P52497 →
P24583 — 0.992 P24583 →
PAK3 Serine/threonine-protein kinase PAK 3 0.992 landscape →
U4PR86 — 0.992 U4PR86 →
Q8RX66 — 0.992 Q8RX66 →
A0A1D9QMS2 — 0.991 A0A1D9QMS2 →
A2ZMH2 — 0.991 A2ZMH2 →
Q8CIP4 — 0.991 Q8CIP4 →
Q9LV37 — 0.991 Q9LV37 →
O75011 — 0.991 O75011 →
P25333 — 0.991 P25333 →
Q8RXT4 — 0.990 Q8RXT4 →
Q01919 — 0.990 Q01919 →
P12688 — 0.990 P12688 →
Q9NB31 — 0.990 Q9NB31 →
Q5RD00 — 0.990 Q5RD00 →
Q8BRK8 — 0.989 Q8BRK8 →
O94235 — 0.989 O94235 →
O43078 — 0.989 O43078 →